Partial
Mostly Aligned
Patient Risk:
Low
Summary
The response correctly matches key label facts about Stelara being an IL-12/IL-23 antagonist monoclonal antibody and the labeled indications for plaque psoriasis, Crohn’s disease, and ulcerative colitis. However, several mechanistic claims are overstated or not explicitly supported by the provided label text (e.g., ‘blocks the activity’ of IL-12/IL-23, downstream immune activation/T-cell response effects, lower pro-inflammatory cytokines, and ‘rather than broadly suppress the immune system’).
Category Scores
Accurate Statements
Stelara (ustekinumab) is a monoclonal antibody.
11 DESCRIPTION: 'Ustekinumab ... is a human IgG1κ monoclonal antibody.'
Stelara targets cytokines involved in inflammatory signaling.
12.1 Mechanism of Action: IL-12 and IL-23 are 'cytokines ... involved in inflammatory and immune responses.'
Stelara binds to interleukin-12 (IL-12).
12.1 Mechanism of Action: ustekinumab 'binds with specificity to the p40 protein subunit used by both the IL-12 and IL-23 cytokines.'
Stelara binds to interleukin-23 (IL-23).
12.1 Mechanism of Action: ustekinumab 'binds with specificity to the p40 protein subunit used by both the IL-12 and IL-23 cytokines.'
Stelara is used in moderate-to-severe plaque psoriasis.
1.1 Plaque Psoriasis: 'moderate to severe plaque psoriasis.'
Stelara is used in Crohn’s disease.
1.3 Crohn's Disease: 'moderately to severely active Crohn's disease.'
Stelara is used in ulcerative colitis.
1.4 Ulcerative Colitis: 'moderately to severely active ulcerative colitis.'
Stelara is used in inflammatory bowel disease indications.
1.3 Crohn's Disease and 1.4 Ulcerative Colitis (both are labeled indications).
Unsupported Statements
Blocking IL-12 and IL-23 reduces downstream immune activation associated with inflammatory disease.
The provided label text describes disruption of IL-12/IL-23 mediated signaling and cytokine cascades, but does not explicitly state that this reduces 'downstream immune activation' in the manner claimed.
By inhibiting IL-12 and IL-23, Stelara interferes with pathways that promote inflammatory T-cell responses.
The label supports involvement of IL-12/IL-23 in CD4+ T-cell differentiation/activation and that signaling is disrupted, but does not explicitly support the specific phrasing about 'inflammatory T-cell responses.'
Inhibiting IL-12 and IL-23 helps lower the production of pro-inflammatory cytokines.
The provided label excerpt does not explicitly state 'lower the production of pro-inflammatory cytokines.'
Stelara reduces immune-driven inflammation seen in conditions such as psoriasis.
The label excerpt supports treatment indication for plaque psoriasis and mechanistic links to inflammatory/immune responses, but does not explicitly state 'immune-driven inflammation' reduction in the specific terms used.
Stelara is designed to block specific immune signals (IL-12/IL-23) rather than broadly suppress the immune system.
The provided label excerpt describes IL-12/IL-23 antagonism, but does not explicitly contrast this with 'broadly suppress the immune system.'
Contradictions
Low
AI Statement
Stelara blocks the activity of IL-12.
Label Reference
12.1 Mechanism of Action
Low
AI Statement
Stelara blocks the activity of IL-23.
Label Reference
12.1 Mechanism of Action
Important Omissions
The extracted claims do not include dosing/administration, contraindications, boxed warnings, safety monitoring, or other core safety labeling elements; these cannot be evaluated from the provided label sections.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Low
The claims are primarily mechanistic/wording-based and indication-based; no contraindications, dosing, or safety-critical directives are asserted in the response. Some mechanistic statements are overstated/not explicitly supported by the provided label excerpt, which could affect interpretive accuracy but is less likely to directly drive unsafe use compared with dosing or contraindication errors.
Regulatory Assessment
| On Label |
Yes |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Mostly Aligned
Primary Issue
Several mechanism-of-action claims go beyond the provided label wording (e.g., explicit 'blocks the activity' and specific downstream effects and immune-suppression comparison).
Suggested Improvement
Rephrase mechanistic claims to align with label language in 12.1 (e.g., 'binds to the p40 subunit used by IL-12 and IL-23' and 'disrupts IL-12/IL-23 mediated signaling and cytokine cascades') without adding unsupported downstream effects or comparisons to broad immune suppression.